Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor

George Morstyn, Graham J. Lieschke, William Sheridan, Judy Layton, Jonathan Cebon, Richard M. Fox

Research output: Contribution to journalArticleResearchpeer-review

52 Citations (Scopus)

Abstract

Bacterially synthesized human granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) have been studied to determine if they could prevent or reduce the neutropenia caused by chemotherapy. Our studies suggest that 10 μg/kg/day of G-CSF administered as a continuous subcutaneous infusion abrogates the neutropenia associated with a standard dose of melphalan. G-CSF produced a rapid increase of neutrophil levels, was well-tolerated, and was associated with only one frequent adverse effect: bone pain. GM-CSF, administered in doses ranging from 3 to 15 μg/kg/day subcutaneously, appeared to be useful in abrogating the neutropenia associated with chemotherapy, producing elevations in neutrophils, eosinophils, and monocytes. Although GM-CSF was relatively well-tolerated, several adverse effects, including bone pain, rashes, and fluid retention, were observed. The initial dose of GM-CSF in some patients produced a reaction that was characterized by hypoxia.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalSeminars in Hematology
Volume26
Issue number2 SUPPL. 2
Publication statusPublished - Apr 1989
Externally publishedYes

Cite this